Technical Analysis for NKTR - Nektar Therapeutics

Grade Last Price % Change Price Change
grade D 79.96 -0.77% -0.62
NKTR closed down 0.77 percent on Friday, May 25, 2018, on 59 percent of normal volume.

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical NKTR trend table...

Date Alert Name Type % Chg
May 25 Multiple of Ten Bearish Other 0.00%
May 24 180 Bearish Setup Bearish Swing Setup -0.77%
May 24 Outside Day Range Expansion -0.77%
May 23 NR7 Range Contraction -3.43%
May 23 NR7-2 Range Contraction -3.43%
May 22 NR7 Range Contraction -2.43%
May 18 Multiple of Ten Bullish Other -6.26%
May 18 Overbought Stochastic Strength -6.26%
May 17 Multiple of Ten Bearish Other 0.92%
May 16 1,2,3 Retracement Bearish Bearish Swing Setup -6.81%

Older signals for NKTR ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms. Its product pipeline consists of drug candidates in various therapeutic areas, including oncology, pain, anti-infectives, and immunology. The company's drug candidates in clinical development stage comprise naloxegol, an opioid antagonist that is in Phase 3 clinical trail for the treatment of opioid-induced constipation; BAY41-6551 that has completed Phase 2 clinical trail to treat gram-negative pneumonias; NKTR-181, a mu-opioid analgesic molecule, which is in Phase 2 clinical trail for chronic pain; and NKTR-192 that is in Phase 1 to treat acute pain. Its other product candidates comprise etirinotecan pegol, a topoisomerase I inhibitor, which is in Phase 3 clinical trial for the treatment of metastatic breast cancer; in Phase 2 clinical trail for ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat metastatic colorectal cancer that completed Phase I clinical trial. In addition, the company offers preclinical drug candidates comprising opioid/NKTR-118 for the treatment of chronic pain; NKTR-171 to treat neuropathic pain; and NKTR-214, a cytokine immunostimulatory therapy for the treatment of oncology. Nektar Therapeutics has collaboration with Bayer Healthcare LLC to develop BAY41-6551 (NKTR-061, Amikacin Inhale), which is an inhaled solution of amikacin, an aminoglycoside antibiotic; and a license agreement with AstraZeneca AB for the development and commercialization of Oral NKTR-118 and NKTR-119. Further, it has various license, manufacturing, and supply agreements for its technology with biotechnology and pharmaceutical companies, such as Affymax, Amgen, MAP Pharmaceuticals, Merck, Pfizer, Roche, and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.
Is NKTR a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 111.36
52 Week Low 17.51
Average Volume 2,986,790
200-Day Moving Average 59.9308
50-Day Moving Average 91.3158
20-Day Moving Average 81.394
10-Day Moving Average 82.342
Average True Range 4.8537
ADX 29.08
+DI 16.03
-DI 24.62
Chandelier Exit (Long, 3 ATRs ) 72.3189
Chandelier Exit (Short, 3 ATRs ) 85.2511
Upper Bollinger Band 86.8965
Lower Bollinger Band 75.8915
Percent B (%b) 0.37
BandWidth 13.520653
MACD Line -2.1572
MACD Signal Line -2.7335
MACD Histogram 0.5763
Fundamentals Value
Market Cap 12.5 Billion
Num Shares 156 Million
EPS -1.40
Price-to-Earnings (P/E) Ratio -57.11
Price-to-Sales 27.79
Price-to-Book 1075.45
PEG Ratio 3.31
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 84.11
Resistance 3 (R3) 84.31 83.13 83.42
Resistance 2 (R2) 83.13 82.08 83.03 83.19
Resistance 1 (R1) 81.55 81.42 80.96 81.34 82.96
Pivot Point 80.37 80.37 80.07 80.27 80.37
Support 1 (S1) 78.78 79.31 78.19 78.58 76.96
Support 2 (S2) 77.60 78.66 77.50 76.73
Support 3 (S3) 76.02 77.60 76.50
Support 4 (S4) 75.81